Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 2
2005 1
2006 1
2007 1
2008 1
2009 3
2010 1
2011 1
2013 2
2014 1
2016 4
2017 2
2018 1
2019 4
2020 5
2021 4
2022 5
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Clinical relevance of exosome-derived microRNAs in Ovarian Cancer: Looking for new tumor biological fingerprints.
Fanale D, Corsini LR, Bono M, Randazzo U, Barraco N, Brando C, Cancelliere D, Contino S, Giurintano A, Magrin L, Pedone E, Perez A, Piraino P, Pivetti A, Giovanni ED, Russo TDB, Prestifilippo O, Gennusa V, Pantuso G, Russo A, Bazan V. Fanale D, et al. Among authors: pantuso g. Crit Rev Oncol Hematol. 2024 Jan;193:104220. doi: 10.1016/j.critrevonc.2023.104220. Epub 2023 Nov 29. Crit Rev Oncol Hematol. 2024. PMID: 38036154 Review.
Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer.
Fanale D, Brando C, Corsini LR, Cutaia S, Di Donna MC, Randazzo U, Filorizzo C, Lisanti C, Magrin L, Gurrera V, Romano R, Dimino A, Bazan Russo TD, Olive D, Vieni S, Pantuso G, Giordano A, Chiantera V, Russo A, Bazan V, Iovanna JL. Fanale D, et al. Among authors: pantuso g. BMC Cancer. 2023 May 13;23(1):437. doi: 10.1186/s12885-023-10911-5. BMC Cancer. 2023. PMID: 37179293 Free PMC article.
Navigating the liquid biopsy Minimal Residual Disease (MRD) in non-small cell lung cancer: Making the invisible visible.
Gristina V, La Mantia M, Peri M, Iacono F, Barraco N, Perez A, Viscardi G, Cutaia S, Russo TDB, Anwar Z, Incorvaia L, Fulfaro F, Vieni S, Pantuso G, Graceffa G, Russo A, Galvano A, Bazan V. Gristina V, et al. Among authors: pantuso g. Crit Rev Oncol Hematol. 2023 Feb;182:103899. doi: 10.1016/j.critrevonc.2022.103899. Epub 2022 Dec 31. Crit Rev Oncol Hematol. 2023. PMID: 36596401 Free article. Review.
Can circulating PD-1, PD-L1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels enhance prognostic power of CA125 in patients with advanced high-grade serous ovarian cancer?
Fanale D, Corsini LR, Brando C, Cutaia S, Di Donna MC, Filorizzo C, Lisanti MC, Randazzo U, Magrin L, Romano R, Bazan Russo TD, Olive D, Vieni S, Pantuso G, Chiantera V, Russo A, Bazan V, Iovanna JL. Fanale D, et al. Among authors: pantuso g. Front Oncol. 2022 Sep 21;12:946319. doi: 10.3389/fonc.2022.946319. eCollection 2022. Front Oncol. 2022. PMID: 36212445 Free PMC article.
MUTYH-associated tumor syndrome: The other face of MAP.
Magrin L, Fanale D, Brando C, Corsini LR, Randazzo U, Di Piazza M, Gurrera V, Pedone E, Bazan Russo TD, Vieni S, Pantuso G, Russo A, Bazan V. Magrin L, et al. Among authors: pantuso g. Oncogene. 2022 Apr;41(18):2531-2539. doi: 10.1038/s41388-022-02304-y. Epub 2022 Apr 14. Oncogene. 2022. PMID: 35422474 Review.
Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?
Fanale D, Corsini LR, Scalia R, Brando C, Cucinella A, Madonia G, Dimino A, Filorizzo C, Barraco N, Bono M, Fiorino A, Magrin L, Sciacchitano R, Perez A, Russo TDB, Pantuso G, Russo A, Bazan V. Fanale D, et al. Among authors: pantuso g. Crit Rev Oncol Hematol. 2022 Feb;170:103597. doi: 10.1016/j.critrevonc.2022.103597. Epub 2022 Jan 13. Crit Rev Oncol Hematol. 2022. PMID: 35033663 Review.
Not all KIT 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs).
Incorvaia L, Badalamenti G, Fanale D, Vincenzi B, Luca I, Algeri L, Barraco N, Brando C, Bonasera A, Bono M, Castiglia M, Cancelliere D, Cani M, Corsini LR, Fiorino A, Galvano A, Pedone E, Perez A, Pivetti A, Graceffa G, Pantuso G, Cabibi D, Russo A, Bazan V. Incorvaia L, et al. Among authors: pantuso g. Ther Adv Med Oncol. 2021 Sep 30;13:17588359211049779. doi: 10.1177/17588359211049779. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 34616493 Free PMC article.
41 results